Michael Cymbor, OD
Optometrist · State College, PANPI 1144217274
Payments from drug & device makers
Across 354 payments — averaging $447.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Optovue, Inc.$46K
- Coopervision Inc.$45K
- LKC Technologies, Inc.$36K
- Visionix USA, Inc$7K
- Thea Pharma Inc.$6K
- Topcon Healthcare, Inc.$3K
- plus $16K from 26 others
Across 13 payments — averaging $13,005 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Coopervision Inc.$137K
- Bausch Health US, LLC$32K
What the payments were for
- Consulting fees$12,90311%
- Speaking & faculty fees$91,06975%
- Travel & lodging$2,5952%
- Food & beverage$14,12212%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Optovue, Inc. | 18 | $45,942 |
| Coopervision Inc. | 62 | $44,790 |
| LKC Technologies, Inc. | 34 | $36,455 |
| Visionix USA, Inc | 4 | $6,808 |
| Thea Pharma Inc. | 13 | $5,570 |
| Topcon Healthcare, Inc. | 21 | $2,801 |
| Quidel Corporation | 14 | $2,656 |
| NEW World Medical,inc. | 2 | $2,650 |
| AbbVie(2 entities) | 24 | $1,671 |
| Sight Sciences, Inc. | 5 | $1,577 |
| Shire North American Group Inc | 7 | $1,033 |
| Apellis Pharmaceuticals, Inc. | 1 | $946 |
| Kala Pharmaceuticals, Inc. | 12 | $915 |
| Notal Vision, Inc. | 1 | $839 |
| Bausch & Lomb Americas Inc. | 30 | $696 |
| Alcon | 15 | $442 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 23 | $401 |
| Biotissue Holdings Inc. | 13 | $328 |
| Maculogix, Inc. | 4 | $288 |
| Tarsus Pharmaceuticals, Inc. | 7 | $265 |
| Sun Pharmaceutical Industries Inc. | 5 | $225 |
| Novartis | 10 | $182 |
| Oyster Point Pharma, Inc. | 6 | $178 |
| Johnson & Johnson Vision Care, Inc. | 8 | $152 |
| Glaukos Corporation | 3 | $152 |
| Aerie Pharmaceuticals, Inc. | 2 | $151 |
| Dompe US, Inc. | 3 | $129 |
| Heru, Inc. | 1 | $110 |
| Alcon Research LLC | 3 | $50 |
| Amgen | 1 | $22 |
| Akorn Operating Company LLC | 1 | $13 |
| Optos, Inc. | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Solix System$35,000
- RETEVAL$17,250
- AngioVue$11,201
- iVue$3,100
- OPTICAL COHERENCE TOMOGRAPHY HOCT-1F$2,808
- Ahmed Glaucoma Valve$2,650
- Kahook Dual Blade$2,650
- IYUZEH$2,152
- Sensor Strip Electrodes$1,998
- TEARCARE SYSTEM$1,500
- Clariti Contact Lens$1,379
- DURYSTA$1,247
- Eye Health$1,200
- LUMIGAN$1,125
- XEN GLAUCOMA TREATMENT SYSTEM$1,125
- InflammaDry$1,000
- XIIDRA$930
- Non-Product Brand Specific$778
- EYSUVIS$700
- MyDay Contact Lens$465
How this compares
$158,447 in reported general payments places this provider in the 95th percentile of 2,165 optometrist providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OxervateCenegermin-Bkbj | 23 | $1,253,223 |
| XdemvyLotilaner | 32 | $60,186 |
| MieboPerfluorohexyloctane/Pf | 41 | $29,507 |
| Cyclosporine | 66 | $26,348 |
| VyzultaLatanoprostene Bunod | 74 | $25,944 |
| XiidraLifitegrast | 17 | $25,162 |
| TyrvayaVarenicline Tartrate | 23 | $21,192 |
| LumiganBimatoprost | 40 | $16,974 |
| RestasisCyclosporine | 20 | $16,705 |
| RhopressaNetarsudil Mesylate | 34 | $12,898 |
| TafluprostTafluprost/Pf | 42 | $10,147 |
| RocklatanNetarsudil Mesylat/Latanoprost | 16 | $9,663 |
| CombiganBrimonidine Tartrate/Timolol | 16 | $6,243 |
| ZioptanTafluprost/Pf | 15 | $6,125 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 18 | $5,274 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Dompe US, Inc.Oxervate | $129 | $1,253,22323 claims |
| Bausch & Lomb Americas Inc.Miebo, Vyzulta, Xiidra | $696 | $80,613132 claims |
| Tarsus Pharmaceuticals, Inc.Xdemvy | $265 | $60,18632 claims |
| AbbVieLumigan, Restasis, Combigan | $1,671 | $39,92276 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan | $151 | $22,56150 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $178 | $21,19223 claims |
| AlconSimbrinza | $442 | $5,27418 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $401 | $5,00533 claims |
| Thea Pharma Inc.Iyuzeh | $5,570 | $4,18315 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,165 optometrist providers in Pennsylvania.
Other optometrist in State College
- Michael TaloneState College$14K
- James DeomHazle Township$793K
- Gregory CaldwellDuncansville$547K
- Glenn CorbinWyomissing$426K
- Leslie O DellNew Freedom$409K
- Kevin BistlinePlymouth Meeting$302K
- Thomas KislanStroudsburg$267K
- Erick HendersonPittsburgh$266K
- Natasha HindmanCranberry Twp$179K
- Ryan YealyLancaster$164K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.